On November 17, 2026 OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, reported its manufacturing and supply partnership with Aura Biosciences, Inc. ("Aura") (NASDAQ: AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura’s lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aura’s programme is being supported from OXB’s process and analytical development facility in Bedford, Massachusetts, and FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, which brings drug substance and fill and finish capabilities together on one site. OXB has initiated technical transfer in preparation for process performance qualification (PPQ) and commercial production. Together, these activities will support Aura’s manufacturing readiness for late-stage clinical development, potential future regulatory filings and commercialisation.
This partnership reflects OXB’s leading position in the space, drawing on more than 30 years of viral vector process development, analytical and GMP manufacturing experience into clinical and commercial stages.
Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: "As Aura advances bel-sar through Phase 3 development, a well-characterised and robust manufacturing process is critical. OXB brings extensive experience supporting complex viral vector programmes through process characterisation, PPQ and towards commercialisation. Supporting this promising candidate from our site in Durham, North Carolina, gives Aura experienced late-stage process and manufacturing teams at a site built for commercial-scale production. This also represents an exciting opportunity for OXB to step into VDC manufacturing, an adjacent segment that sits close to our core viral vector expertise and this partnership demonstrates our ability to provide a world-class service offering in this area."
(Press release, Oxford BioMedica, NOV 17, 2026, View Source [SID1234674842])